BDBM513780 US11091495, Example 141::US11220509, Example 2
SMILES CCOC(=O)c1cn2c(NCc3c4CCOc4ccc3F)ncc(Br)c2n1
InChI Key InChIKey=POJLFXSHDKTYNB-UHFFFAOYSA-N
Data 9 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 9 hits for monomerid = 513780
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 500nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair